- Price
- $22.76
- Day
- +3.29%
- Mkt Cap
- $185.23M
- 52W Range
- $5.26 – $24.92
- Volume
- 54.1K
- Beta
- 0.56
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
LOUISVILLE, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in a fireside chat and host in-person 1x1 investor meetings at Canaccord Genuity's 46th Annual Growth Conference, which will be held from August 11-12, 2026.
Read full article
bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock offers better long-term upside? Let's dive in.
Read full article
Shares of Biodesix, Inc. (NASDAQ: BDSX - Get Free Report) have received an average rating of "Moderate Buy" from the five brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on
Read full article
LOUISVILLE, Colo., July 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, 2026 after the close of trading on Wednesday, August 5. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Read full article